Effects of the NOP agonist SCH221510 on producing and attenuating reinforcing effects as measured by drug self-administration in rats

Aklin, 2012, Risk-taking propensity as a predictor of induction onto naltrexone treatment for opioid dependence, J. Clin. Psychiat., 73, e1056, 10.4088/JCP.09m05807

Andero, 2013, Amygdala-dependent fear is regulated by oprl1 in mice and humans with PTSD, Sci. Transl. Med., 5, 188ra173, 10.1126/scitranslmed.3005656

Bardo, 2000, Conditioned place preference: what does it add to our preclinical understanding of drug reward?, Psychopharmacology (Berl), 153, 31, 10.1007/s002130000569

Baylon, 2000, Comparative abuse liability of intravenously administered remifentanil and fentanyl, J. Clin. Psychopharmacol., 20, 597, 10.1097/00004714-200012000-00002

Bertz, 2013, Acquisition of responding with a remifentanil-associated conditioned reinforcer in the rat, Psychopharmacology (Berl), 229, 235, 10.1007/s00213-013-3102-0

Calo, G., Guerrini, R., 2013. Medical chemistry, pharmacology, and biological actions of peptide ligands selective for the nociceptin/orphanin FQ receptor. In: Ko, M.C., Husbands, S.M. (Eds.), Research and Development of Opioid-Related Ligands. American Chemical Society Symposium Series 1131, Washington DC, USA, pp. 275–325. doi:10.1021/bk-2013-1131.ch015

Carter, 2009, Principles of laboratory assessment of drug abuse liability and implications for clinical development, Drug Alcohol Depen., 105, S14, 10.1016/j.drugalcdep.2009.04.003

Chuck, 2006, Comparison between multiple behavioral effects of peripheral ethanol administration in rats: sedation, ataxia, and bradykinesia, Life Sci., 79, 154, 10.1016/j.lfs.2005.12.045

Collins, 2007, Drug and reinforcement history as determinants of the response-maintaining effects of quinpirole in the rat, J. Pharmacol. Exp. Ther., 323, 599, 10.1124/jpet.107.123042

Cooper, 2008, Morphine deprivation increases self-administration of the fast- and short-acting mu-opioid receptor agonist remifentanil in the rat, J. Pharmacol. Exp. Ther., 326, 920, 10.1124/jpet.108.139196

Cremeans, 2012, Roles of mu-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates, J. Pharmacol. Exp. Ther., 343, 72, 10.1124/jpet.112.194308

Crespo, 2008, Nucleus accumbens core acetylcholine is preferentially activated during acquisition of drug- vs food-reinforced behavior, Neuropsychopharmacology, 33, 3213, 10.1038/npp.2008.48

Devine, 1996, The novel neuropeptide orphanin FQ fails to produce conditioned place preference or aversion, Brain Res., 727, 225, 10.1016/0006-8993(96)00476-3

Di Giannuario, 2000, Nociceptin differentially affects morphine-induced dopamine release from the nucleus accumbens and nucleus caudate in rats, Peptides, 21, 1125, 10.1016/S0196-9781(00)00250-3

Di Giannuario, 1999, Orphanin FQ reduces morphine-induced dopamine release in the nucleus accumbens: a microdialysis study in rats, Neurosci. Lett., 272, 183, 10.1016/S0304-3940(99)00579-0

Dodds, T.M., 2013. Commentary on the current status of clinically used analgesics. In: Ko, M.C., Husbands, S.M. (Eds.), Research and Development of Opioid-Related Ligands. American Chemical Society Symposium Series 1131, Washington DC, USA, pp. 3–4. doi:10.1021/bk-2013-1131.ch001

Haney, 2008, Controversies in translational research: drug self-administration, Psychopharmacology (Berl), 199, 403, 10.1007/s00213-008-1079-x

Jenck, 2000, A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat, Proc. Natl. Acad. Sci. U. S. A., 97, 4938, 10.1073/pnas.090514397

Kawahara, 2013, Food reward-sensitive interaction of ghrelin and opioid receptor pathways in mesolimbic dopamine system, Neuropharmacology, 67, 395, 10.1016/j.neuropharm.2012.11.022

Ko, 2009, Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys, Neuropsychopharmacology, 34, 2088, 10.1038/npp.2009.33

Lambert, 2008, The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential, Nat. Rev. Drug Discov., 7, 694, 10.1038/nrd2572

Le Pen, 2002, The orphanin receptor agonist RO 64-6198 does not induce place conditioning in rats, Neuroreport, 13, 451, 10.1097/00001756-200203250-00018

Lee, 2003, Characterization of scratching responses in rats following centrally administered morphine or bombesin, Behav. Pharmacol., 14, 501, 10.1097/00008877-200311000-00002

Lin, 2013, The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability, ACS Chem. Neurosci., 4, 214, 10.1021/cn300124f

Linz, K., Christoph, T., Schiene, K., Koch, T., Englberger, W., 2013. GRT-TA2210, a Selective NOP Receptor Agonist, is Active in Mouse Models of Inflammatory and Neuropathic Pain, EFIC – 8th “Pain in Europe” Congress, Florence, Italy.

Mogali, S., Comer, S.D., 2013. Treatment of pain and opioid abuse. In: Ko, M.C., Husbands, S.M. (Eds.), Research and Development of Opioid-Related Ligands. American Chemical Society Symposium Series 1131, Washington DC. USA, pp. 39–60. doi:10.1021/bk-2013-1131.ch004

O׳Connor, 2011, The predictive validity of the rat self-administration model for abuse liability, Neurosci. Biobehav. Rev., 35, 912, 10.1016/j.neubiorev.2010.10.012

O׳Connor, 2010, Tramadol acts as a weak reinforcer in the rat self-administration model, consistent with its low abuse liability in humans, Pharmacol. Biochem. Behav., 96, 279, 10.1016/j.pbb.2010.05.018

Obara, 2005, Spinal and local peripheral antiallodynic activity of Ro64-6198 in neuropathic pain in the rat, Pain, 116, 17, 10.1016/j.pain.2005.03.012

Podlesnik, 2011, The effects of nociceptin/orphanin FQ receptor agonist Ro 64-6198 and diazepam on antinociception and remifentanil self-administration in rhesus monkeys, Psychopharmacology (Berl), 213, 53, 10.1007/s00213-010-2012-7

Rutten, 2011, Pharmacological blockade or genetic knockout of the NOP receptor potentiates the rewarding effect of morphine in rats, Drug Alcohol Depen., 114, 253

Schroder, 2014, Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists, Br. J. Pharmacol., 10.1111/bph.12744

Servin, 2008, Remifentanil and other opioids, Handb. Exp. Pharmacol., 283, 10.1007/978-3-540-74806-9_14

Shannon, 2002, Comparison of the peripheral and central effects of the opioid agonists loperamide and morphine in the formalin test in rats, Neuropharmacology, 42, 253, 10.1016/S0028-3908(01)00173-3

Sukhtankar, D.D., Ko, M.C., 2013. Pharmacological Investigation of NOP-Related ligands as analgesics without abuse liability. In: Ko, M.C.Husbands, S.M,. (Eds.), Research and Development of Opioid-Related Ligands. American Chemical Society Symposium Series 1131, Washington DC, USA, pp. 393–416. doi:10.1021/bk-2013-1131.ch018

Sukhtankar, 2014, Differential effects of opioid-related ligands and NSAIDs in nonhuman primate models of acute and inflammatory pain, Psychopharmacology (Berl), 231, 1377, 10.1007/s00213-013-3341-0

Sukhtankar, 2013, Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/mu-opioid receptor ligands in mouse models of neuropathic and inflammatory pain, J. Pharmacol. Exp. Ther., 346, 11, 10.1124/jpet.113.203984

Taber, 1998, Opioid receptor modulation of feeding-evoked dopamine release in the rat nucleus accumbens, Brain Res., 785, 24, 10.1016/S0006-8993(97)01124-4

Varty, 2005, Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species, Psychopharmacology (Berl), 182, 132, 10.1007/s00213-005-0041-4

Varty, 2008, The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 221510), J. Pharmacol. Exp. Ther., 326, 672, 10.1124/jpet.108.136937

Whiteside, G.T., Kyle, D.J., 2013. A review of the NOP (ORL-1)-Nociceptin/Orphanin FQ system covering receptor structure, distribution, role in analgesia and reward and interactions with other receptors, In: Ko, M.C., Husbands, S.M. (Eds.), Research and Development of Opioid-Related Ligands. American Chemical Society Symposium Series 1131, Washington DC, USA, pp. 327–368. doi:10.1021/bk-2013-1131.ch016

Wightman, 2012, Likeability and abuse liability of commonly prescribed opioids, J. Med. Toxicol., 8, 335, 10.1007/s13181-012-0263-x

Witkin, 2014, The biology of nociceptin/orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence, Pharmacol. Ther., 141, 283, 10.1016/j.pharmthera.2013.10.011

Zaveri, 2011, The nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medications, Curr. Top Med. Chem., 11, 1151, 10.2174/156802611795371341